The association of bone mineral density with HIV infection and antiretroviral treatment in women

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1049-1058

  Anastos, Kathryn ^a   Lu, Dalian ^b   Shi, Qiuhu ^c   Mulligan, Kathleen ^d   Tien, Phyllis C ^d,e   Freeman, Ruth ^f   Cohen, Mardge H ^g   Justman, Jessica ^h   Hessol, Nancy A ^d  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Data Solutions LLC   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Jr Hospital of Cook County   (United States)

^h Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; RISK FACTORS;

EID: 36148939489     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Paton NI, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997; 61:30-32.
2. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-F67.
3. Arnsten JH, Freeman R, Howard AA, et al. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42:1014-1020.
4. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIV-infected women. AIDS 2004; 18:475-483.
5. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91:2938-2945.
6. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 2001; 86:3533-3539.
7. Moore AL, Vashisht A, Sabin CA, et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001; 15:1731-1733.
8. McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74:679-686.
9. Vescini F, Borderi M, Buffa A, et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr 2003; 33:405-407.
10. Lawal A, Engelson ES, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001; 15:278-280.
11. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482-490.
12. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923.
13. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15:1275-1280.
14. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-709.
15. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15:975-982.
16. Singh K, Moyle GM. Bone mineral abnormalities in persons with HIV infection: signal or noise. AIDS Reader 2006; 16:407.
17. Bainbridge KE, Sowers MF, Crutchfield M, et al. Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 2002; 156:410-417.
18. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359:1761-1767.
19. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:298-302.
20. + cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:448-454.
21. Centers for Disease Control and Prevention. Cases of HIV-infection and AIDS in the United States 2004. HIV/AIDS Surveillance Report 2005; Volume 16.
22. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
23. Hessol NA, Schneider M, Greenblatt RM, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol 2001; 154:563-573.
24. Binkley N, Kiebzak GM, Lewiecki EM, et al. Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res 2005; 20:195-201.
25. Calvelli T, Denny T, Paxton H, Gelman R, Kagan J. Guidelines for flow cytometric immunophenotyping. Cytometry 1993; 14:702-715.
26. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84:145-150.
27. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-534.
28. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor (TNF) α and soluble TNF receptors in human immunodeficiency virus type 1 infection- correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169:420-424.
29. Andersson J, Fehniger TE, Patterson BK, et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998; 12:F123-F129.
30. Behbahani H, Landay A, Patterson BK, et al. Normalization of immune activation in lymphoid tissue following highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:150-156.
31. Lew E, Gallagher L, Kuehnert M, et al. Intracellular cytokines in the acute response to highly active antiretroviral therapy. AIDS 2001; 15:1665-1670.
32. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72-75.
33. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res 2005; 20:185-194.
34. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815-2822.
35. Dobs A, Brown T. Metabolic abnormalities in HIV disease and injection drug use. J Acquir Immune Defic Syndr 2002; 31 Suppl 2:S70-S77.